Sugi Predict

Sugi Predict / Compounds / SCHEMBL4609607

SCHEMBL4609607

SCHEMBL4609607

COc1cc(S(=O)(=O)N(C)C)ccc1N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.66
▸ ALDH1A1 P00352 7/20 0.55
▸ POLB P06746 2/20 0.55
▸ PKM P14618 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ CYP3A4 P08684 2/20 0.53
▸ TSHR P16473 2/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ HTT P42858 2/20 0.49
▸ MAPK1 P28482 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ HTR2C P28335 1/20 0.44
▸ HTR2B P41595 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ MMP1 P03956 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6123467 0.86 MAPT (0.61) MAPTALDH1A1POLBPKMMEN1
SCHEMBL7204252 0.84 MAPT (0.72) MAPTALDH1A1POLBTSHRHTT
SCHEMBL9400292 0.82 ALDH1A1 (0.70) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL3259829 0.82 TSHR (0.68) MAPTALDH1A1POLBPKMCYP3A4
SCHEMBL23144411 0.81 KMT2A (0.54) MAPTALDH1A1MEN1KMT2ACYP3A4
SCHEMBL29811288 0.81 KMT2A (0.54) MAPTALDH1A1MEN1KMT2ACYP3A4
SCHEMBL8777970 0.80 MAPT (0.55) MAPTALDH1A1POLBPKMMEN1
SCHEMBL358860 0.80 SMN1; SMN2 (0.59) MAPTALDH1A1POLBPKMCYP3A4
SCHEMBL30184665 0.80 SMN1; SMN2 (0.59) MAPTALDH1A1POLBPKMCYP3A4
SCHEMBL30291384 0.80 MAPT (0.55) MAPTALDH1A1POLBPKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-04-09 — — US disclosed
EP-4644387-A2 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2025-11-05 — — EP disclosed
US-12428406-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 — — EP disclosed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 — — WO disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed
US-9334286-B2 Pharmacologically active compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-05-10 — — US disclosed
US-20150218181-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-08-06 — — US disclosed
US-20150218181-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-08-06 — — US disclosed
US-20150218181-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-08-06 — — US disclosed
WO-2014037751-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-03-13 — — WO disclosed
EP-1417264-B1 NOVEL AZO PIGMENTS CLARIANT PRODUKTE DEUTSCHLAND (DE) 2008-10-15 — — EP disclosed
US-6872245-B2 Azo pigments CLARIANT GMBH (DE) 2005-03-29 — — US disclosed
US-20040231557-A1 Novel azo pigments CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2004-11-25 — — US disclosed
EP-1417264-A1 NOVEL AZO PIGMENTS Clariant GmbH (DE) 2004-05-12 — — EP disclosed
WO-2003014227-A1 NOVEL AZO PIGMENTS CLARIANT GMBH (DE) 2003-02-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428406-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS MAPT 4269/4885ALDH1A1 1538/4885POLB 70/4885
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS MAPT 4269/4885ALDH1A1 1538/4885POLB 70/4885
US-20150218181-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS BUB1B, BUB1, PLK1 MAPT 1143/4885ALDH1A1 3651/4885POLB 1139/4885
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 MAPT 2352/4885ALDH1A1 2527/4885POLB 73/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS MAPT 4269/4885ALDH1A1 1538/4885POLB 70/4885
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, MDM2 MAPT 2371/4885ALDH1A1 4027/4885POLB 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.